Published

Polypharmacology or "Pharmacological Promiscuity" In Psychedelic Research: What Are We Missing?

Research with psychedelic drugs has mainly focused on isolated compounds. However, this approach is challenged by the "polypharmacology" paradigm. In this Viewpoint, we suggest that we may be missing something if we do not use the whole product in the case of ayahuasca or mushrooms. After describing how research on psychedelic drugs can be effectively combined with the polypharmacology paradigm, ethical issues are also briefly discussed.

Open source BibTeX RIS

Bibliographic context

Journal: ACS chemical neuroscience
Date: 2020-10-20
Source: PubMed
DOI: 10.1021/acschemneuro.0c00614
PubMed: 33021777

Authors

Ona GS Dos Santos RG Hallak JEC Bouso JC

Watch author

Topics and keywords

psilocybin Pharmacology Other Psychedelics ayahuasca polypharmacology psilocybe psilocybin

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapyNatural Product Research · 2026-06-01 Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31 Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled ConditionsJournal of Fungi · 2026-07-01 Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22 Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17 Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depressionPharmacological Research · 2026-06-10 Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitusHearing Research · 2026-06-03 Corrigendum to “From Prohibited to Prescribed: The Rescheduling of MDMA and Psilocybin in Australia”Drug Science Policy and Law · 2026-05-31